Last 12 months
Inside the activity.
2 purchase rows · 274 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 2 | 29 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 37 |
| Apr 2026 | 0 | 22 |
| May 2026 | 0 | 8 |
| Jun 2026 | 0 | 152 |
| Jul 2026 | 0 | 7 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 6 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 1,386 | $42.84 | $59,376.24 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 12 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 828,830 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 22,779 | $42.19 | $961,046.01 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 11 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 830,216 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 6,686 | $42.84 | $286,428.24 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 10 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,676,075 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive. F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 108,404 | $42.19 | $4,573,564.76 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 9 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,682,761 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive. F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 1,386 | $42.84 | $59,376.24 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 12 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 828,830 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 22,779 | $42.19 | $961,046.01 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 11 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 830,216 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 6,686 | $42.84 | $286,428.24 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 10 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,676,075 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. Read SEC document |
| March 13, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 108,404 | $42.19 | $4,573,564.76 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 9 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,682,761 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 1,819 | $42.52 | $77,343.88 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 8 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 852,995 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 26,452 | $41.94 | $1,109,396.88 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 7 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 854,814 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 8,581 | $42.52 | $364,864.12 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 6 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,791,165 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive. F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 126,066 | $41.94 | $5,287,208.04 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 5 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,799,746 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive. F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 1,819 | $42.52 | $77,343.88 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 8 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 852,995 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 26,452 | $41.94 | $1,109,396.88 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 7 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 854,814 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 8,581 | $42.52 | $364,864.12 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 6 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,791,165 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 126,066 | $41.94 | $5,287,208.04 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 5 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,799,746 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 1,045 | $43.42 | $45,373.90 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 4 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 881,266 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 7,837 | $42.77 | $335,188.49 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 882,311 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10). F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 5,122 | $43.42 | $222,397.24 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,925,812 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive. F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 23:53 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
SaleCommon Stock | 37,180 | $42.77 | $1,590,188.60 |
DisclosureSEC source: 0001415889-24-007894 · form4-03132024_110341.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,930,934 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10). F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 1,045 | $43.42 | $45,373.90 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 4 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 881,266 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive. F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 7,837 | $42.77 | $335,188.49 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 3 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 882,311 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10). F6 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 5,122 | $43.42 | $222,397.24 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 2 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,925,812 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 23:52 UTC |
Booth BruceDirector
|
SaleCommon Stock | 37,180 | $42.77 | $1,590,188.60 |
DisclosureSEC source: 0001415889-24-007890 · form4-03132024_110328.xml · nonDerivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,930,934 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10). F3 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:21 UTC |
Gollob JaredChief Medical Officer
|
SaleCommon Stock | 216 | $43.26 | $9,343.38 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · nonDerivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,740 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:21 UTC |
Gollob JaredChief Medical Officer
|
SaleCommon Stock | 1,106 | $42.39 | $46,885.99 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,956 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:21 UTC |
Gollob JaredChief Medical Officer
|
SaleCommon Stock | 2,022 | $41.41 | $83,738.10 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,062 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:12 UTC |
Jacobs Bruce N.Chief Financial Officer
|
SaleCommon Stock | 255 | $43.26 | $11,030.38 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · nonDerivative · entry 4 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,351 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:12 UTC |
Jacobs Bruce N.Chief Financial Officer
|
SaleCommon Stock | 1,301 | $42.39 | $55,152.51 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · nonDerivative · entry 3 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,606 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:12 UTC |
Jacobs Bruce N.Chief Financial Officer
|
SaleCommon Stock | 2,378 | $41.41 | $98,481.30 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · nonDerivative · entry 2 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,907 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:12 UTC |
Mainolfi NelloDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 530,000 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025085 · ownership.xml · derivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,000 Underlying: Common Stock · 530,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:21 UTC |
Gollob JaredChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 146,250 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · derivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,250 Underlying: Common Stock · 146,250 shares Expires 2034-02-28 F6 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:21 UTC |
Gollob JaredChief Medical Officer
|
GrantCommon Stock | 24,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,084 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:15 UTC |
Chiniara EllenChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 130,531 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025093 · ownership.xml · derivative · entry 2 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,531 Underlying: Common Stock · 130,531 shares Expires 2034-02-28 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:15 UTC |
Chiniara EllenChief Legal Officer
|
GrantCommon Stock | 21,755 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025093 · ownership.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,960 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:16 UTC |
Chadwick Jeremy GChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 80,548 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025097 · ownership.xml · derivative · entry 2 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,548 Underlying: Common Stock · 80,548 shares Expires 2034-02-28 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:16 UTC |
Chadwick Jeremy GChief Operating Officer
|
GrantCommon Stock | 13,425 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025097 · ownership.xml · nonDerivative · entry 1 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,758 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:12 UTC |
Jacobs Bruce N.Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · derivative · entry 5 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2034-02-28 F6 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:12 UTC |
Jacobs Bruce N.Chief Financial Officer
|
GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025083 · ownership.xml · nonDerivative · entry 1 Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,285 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:34 UTC |
Gollob JaredChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-023168 · ownership.xml · derivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,483 Underlying: Common Stock · 400 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:34 UTC |
Gollob JaredChief Medical Officer
|
SaleCommon Stock | 400 | $45.00 | $18,000.00 |
DisclosureSEC source: 0000950170-24-023168 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,709 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:34 UTC |
Gollob JaredChief Medical Officer
|
Exercise / conversionCommon Stock | 400 | $2.08 | $832.00 |
DisclosureSEC source: 0000950170-24-023168 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. Read SEC document |
| February 21, 2024 Filed Feb 21, 2024 23:46 UTC |
Albers Jeffrey W.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,385 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0000950170-24-018246 · ownership.xml · derivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,349 Underlying: Common Stock · 4,385 shares Expires 2030-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023. F4 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date. Read SEC document |
| February 21, 2024 Filed Feb 21, 2024 23:46 UTC |
Albers Jeffrey W.Director
|
SaleCommon Stock | 4,385 | $39.05 | $171,226.80 |
DisclosureSEC source: 0000950170-24-018246 · ownership.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 21, 2024 Filed Feb 21, 2024 23:46 UTC |
Albers Jeffrey W.Director
|
Exercise / conversionCommon Stock | 4,385 | $10.34 | $45,340.90 |
DisclosureSEC source: 0000950170-24-018246 · ownership.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 23:46 UTC |
Albers Jeffrey W.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 615 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0000950170-24-018246 · ownership.xml · derivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,734 Underlying: Common Stock · 615 shares Expires 2030-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023. F4 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 23:46 UTC |
Albers Jeffrey W.Director
|
SaleCommon Stock | 615 | $39.07 | $24,030.88 |
DisclosureSEC source: 0000950170-24-018246 · ownership.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 23:46 UTC |
Albers Jeffrey W.Director
|
Exercise / conversionCommon Stock | 615 | $10.34 | $6,359.10 |
DisclosureSEC source: 0000950170-24-018246 · ownership.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023. Read SEC document |
| February 09, 2024 Filed Feb 10, 2024 00:47 UTC |
Gollob JaredChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 46,137 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-013482 · ownership.xml · derivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,883 Underlying: Common Stock · 46,137 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| February 09, 2024 Filed Feb 10, 2024 00:47 UTC |
Gollob JaredChief Medical Officer
|
SaleCommon Stock | 7,398 | $36.09 | $267,013.05 |
DisclosureSEC source: 0000950170-24-013482 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,709 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.